Clinical trial · Observational
Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help researchers study cancer behavior and test new treatments. Participants diagnosed with sarcoma or with bone or lung metastases from solid tumors will donate leftover tumor tissue and blood collected during their regular medical care. These samples will be used in the lab to build 3D models of the tumor, test drugs, and identify genetic and molecular markers. No treatments or procedures will be given as part of the study.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone and Soft Tissue Tumors | — | UNRESOLVED | — |
| Bone Metastases From Solid Tumors | — | UNRESOLVED | — |
| Lung Metastases | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients with Sarcoma or Bone and Lung Metastases from Solid Tumors
- description
- This group includes male and female patients aged 0-85 years diagnosed with sarcomas or with bone or lung metastases from solid tumors and undergoing in surgical removal of the tumor or performing a biopsy. Only patients whose resection will provide sufficient tumor tissue that exceed what is necessary for pathological diagnosis characterization and banking will be enrolled.
Primary outcomes (1)
- measure
- Number of tumor samples enabling the development of at least three preclinical models
- timeFrame
- 7 years
- description
- Number of patient-derived tumor samples that allow the successful development of at least three distinct preclinical models (e.g., spheroids, explants, scaffold-based cultures, or bioprinted constructs). This outcome assesses the feasibility and robustness of the tissue-based modeling approach.
Secondary outcomes (1)
- measure
- Evaluation of the quality of the models
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients (male or female) diagnosed with sarcoma or with bone or lung metastases from solid tumors * Age between 0 and 85 years * Availability of sufficient and adequate biological material (tumor tissue and/or blood) * Signed informed consent for biobanking (BIOTUM) * Signed informed consent for use of tissue and blood samples in this study Exclusion Criteria: * Diagnosis other than sarcoma or metastases from solid tumors * Missing signed informed consent(s)
References
Publications (0)
Data not yet available